BRAF and neoplasm: Some well-known examples include Vemurafenib, which targets BRAF and modulates the tumor microenvironment to promote T cell infiltration in melanoma (40); Dasatinib, which targets multiple tyrosine kinases and enhances immune cell function in leukemia and solid tumors (41); and Ibrutinib, which inhibits BTK and modulates B-cell receptor signaling in B-cell malignancies (42).